Literature DB >> 1381909

Correlation between detection of anti-viral antibody and histopathological disease activity in an epidemic of hepatitis C.

Y Fukuda1, H Nagura, T Takayama, M Imoto, M Shibata, T Kudo, T Morishima, T Miyamura, Y Nagai.   

Abstract

There was an epidemic of non-A non-B hepatitis in a small area of a town in the central part of Japan, which began with an outbreak of several patients in 1981 and then spread extensively with the result that about one third of the inhabitants showed abnormality in serum liver function tests at the health check performed in 1985. We determined histological diagnoses on that occasion for 167 individuals of the abnormal population and recently assayed antibodies against hepatitis C virus (HCV) for most of their sera left available. Histologically, chronic active hepatitis (CAH) was the major pattern, accounting for 59.3% (99 cases) of the total. Others were chronic persistent hepatitis (CPH) (13.2%), chronic lobular hepatitis (CLH) (16.2%), liver cirrhosis (LC) (6.6%) and fatty liver (4.8%). In the serological studies, the newly developed system to detect antibodies against the viral core protein p 22 was found to be much more sensitive than the conventional system to detect anti C 100-3 antibodies. By using these two methods in combination, we found that 82% were antibody-positive, indicating strong implication of HCV in this epidemic. This was further supported by direct detection of the viral genome in patients' sera by polymerase chain reaction following reverse transcription. We further found a strong correlation between the histological inflammatory activity and the antibody prevalence, since nearly all (97.6%) of the CAH cases were antibody-positive by at least either of the antibody assays, while only about 50% were positive in the less active cases such as CPH and CLH.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381909     DOI: 10.1007/bf01309693

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  11 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis.

Authors:  T Miyamura; I Saito; T Katayama; S Kikuchi; A Tateda; M Houghton; Q L Choo; G Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  The putative nucleocapsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers.

Authors:  K Takeuchi; Y Kubo; S Boonmar; Y Watanabe; T Katayama; Q L Choo; G Kuo; M Houghton; I Saito; T Miyamura
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

4.  The 5'-terminal sequence of the hepatitis C virus genome.

Authors:  H Okamoto; S Okada; Y Sugiyama; S Yotsumoto; T Tanaka; H Yoshizawa; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Jpn J Exp Med       Date:  1990-06

5.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

6.  Prevalence of antibody against the core protein of hepatitis C virus in patients with hepatocellular carcinoma.

Authors:  Y Watanabe; S Harada; I Saito; T Miyamura
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

7.  Serum hepatitis C virus sequences in posttransfusion non-A, non-B hepatitis.

Authors:  M Shibata; T Morishima; T Kudo; T Maki; S Maki; Y Nagai
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

8.  A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan.

Authors:  Y Kubo; K Takeuchi; S Boonmar; T Katayama; Q L Choo; G Kuo; A J Weiner; D W Bradley; M Houghton; I Saito
Journal:  Nucleic Acids Res       Date:  1989-12-25       Impact factor: 16.971

9.  Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus.

Authors:  J Chiba; H Ohba; Y Matsuura; Y Watanabe; T Katayama; S Kikuchi; I Saito; T Miyamura
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

View more
  1 in total

1.  Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease.

Authors:  W H Grotz; T H Peters; H J Schlayer; G Kirste; H Berthold; H Felten; P J Schollmeyer; J W Rasenack
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.